

AstraZeneca Pharma India Limited
 Regd. Office : Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore 560 045
 Statement of financial results for the quarter and year ended 31 March 2019

Sl No.	Particulars	Rs in lakhs except for earnings per share data				
		3 months ended 31/03/2019	Previous 3 months ended 31/12/2018	Corresponding 3 months ended in the previous year 31/03/2018	Year ended 31/03/2019	Previous year ended 31/03/2018
		Refer note 6	Unaudited	Refer note 6	Audited	Audited
1	Revenue					
	a) Revenue from operations	19,030.27	21,519.40	15,072.66	72,829.43	57,198.92
	b) Other income	601.22	349.57	233.82	1,628.52	1,224.76
	Total income	19,631.49	21,868.97	15,306.48	74,457.95	58,423.68
2	Expenses					
	(a) Cost of materials consumed	2,223.71	1,594.29	1,092.07	6,267.23	2,731.01
	(b) Purchase of stock-in-trade	8,091.56	4,156.63	2,472.62	16,983.88	20,421.17
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(4,028.29)	651.47	783.69	(137.78)	(5,099.57)
	(d) Excise duty	-	-	-	-	98.50
	(e) Employee benefits expense	6,041.02	5,108.91	4,429.66	19,739.86	15,039.40
	(f) Depreciation and amortisation expense	390.89	378.10	355.08	1,492.41	1,473.75
	(g) Selling, marketing and distribution expense	2,298.46	1,651.37	2,111.30	7,980.28	7,280.51
	(h) Other expenses	3,766.82	4,268.74	2,656.38	14,865.72	12,098.90
	(i) Finance cost	-	-	-	-	-
	Total expenses	18,784.17	17,809.51	13,900.80	67,191.60	54,043.67
3	Profit / (Loss) before exceptional and extraordinary items and tax (1-2)	847.32	4,059.46	1,405.68	7,266.35	4,380.01
4	Exceptional items	-	-	-	-	-
5	Profit / (Loss) before extraordinary items and tax (3+4)	847.32	4,059.46	1,405.68	7,266.35	4,380.01
6	Extraordinary items	-	-	-	-	-
7	Profit before tax (5+6)	847.32	4,059.46	1,405.68	7,266.35	4,380.01
8	Tax expense					
	- Current tax (Refer note 3)	(148.42)	1,114.91	194.75	1,667.83	899.74
	- Deferred tax	13.36	35.37	888.79	154.45	888.79
	Total tax expense	(135.06)	1,150.28	1,083.54	1,822.28	1,788.53
9	Profit / (Loss) for the period (7-8)	982.38	2,909.18	322.14	5,444.07	2,591.48
10	Other comprehensive income					
	A. Items that will not be reclassified to profit or loss					
	Re-measurement gains/(losses) on post employment benefit obligations	231.31	(60.65)	(633.10)	(92.30)	(350.50)
	Income tax effect on above	(80.83)	21.19	122.48	32.25	122.51
	Total other comprehensive income/ (loss), net of income tax	150.48	(39.46)	(510.62)	(60.05)	(227.99)
	Total comprehensive income for the period (9+10)	1,132.86	2,869.72	(188.48)	5,384.02	2,363.49
11	Paid-up equity share capital (Face value of Rs 2/- per equity share)	500.00	500.00	500.00	500.00	500.00
12	Reserves (excluding revaluation reserves as per balance sheet)	-	-	-	29,580.50	24,193.18
13	Earnings per equity share of Rs 2/- each (basic and diluted)	3.93	11.64	1.29	21.78	10.37

Jagan



Mw

AstraZeneca Pharma India Limited
Regd. Office : Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore 560 045
Statement of financial results for the quarter and year ended 31 March 2019

Notes:

- 1 The financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (as amended) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- 2 The Company has adopted Ind AS 115 "Revenue from Contracts with Customers" with effect from 01 April, 2018 by applying the modified retrospective approach. The impact on account of adoption of Ind AS 115 as compared with Ind AS 18 on the Statement of Assets and Liabilities as at 31 March, 2019 and Statement of Financial Results for the quarter and year ended March 31, 2019 is not material.
- 3 Current tax includes reversal of excess income tax provision of Rs. 751 lakhs pertaining to an earlier year.
- 4 The Company has identified 'Healthcare Segment' as its only reportable segment in accordance with the requirements of Ind AS 108, 'Operating Segments'. Accordingly no segment information has been provided.
- 5 As previously disclosed, by way of a letter dated 1 March 2014, AstraZeneca Pharmaceuticals AB, the promoter of the Company had proposed a voluntary delisting of the Company's equity shares from the National Stock Exchange and the Bombay Stock Exchange. Such proposed delisting is subject to an on-going inquiry with SEBI and that inquiry has not yet been resolved. In any event, based on the passage of time, any potential future proposal for voluntary delisting of the Company would need to be conducted de novo.
- 6 The figures for the quarter ended 31 March, 2019 and 31 March, 2018 are the balancing figures between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the respective financial year which were subjected to review by the statutory auditors.
- 7 Previous period's figures have been regrouped/reclassified, where necessary, to conform with the current period's presentation for the purpose of comparability.
- 8 This statement of financial results and statement of assets and liabilities was reviewed and recommended for approval by the Audit Committee of the Board and subsequently approved by the Board of Directors at their respective meetings held on 24 May 2019.

Place: Bengaluru
Date: 24 May, 2019

By Order of the Board of Directors
For AstraZeneca Pharma India Limited


Gagandeep Singh Bedi
Managing Director



AstraZeneca Pharma India Limited
Regd Office : Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore 560 045
Statement of assets and liabilities

		(Rs in lakhs)	
Sl.No.	Balance Sheet	As at 31 March 2019 (Audited)	As at 31 March 2018 (Audited)
	ASSETS		
1	Non-current assets		
	(a) Property, plant and equipment	7,483.05	7,546.02
	(b) Capital work-in-progress	690.06	357.27
	(c) Financial Assets		
	(i) Loans	286.03	263.85
	(d) Current tax assets	4,644.17	2,356.04
	(e) Deferred tax assets	2,336.92	3,255.29
	(f) Other non-current assets	269.05	184.10
	Sub-total - Non-current assets	15,709.28	13,962.57
2	Current assets		
	(a) Inventories	11,810.74	11,315.10
	(b) Financial Assets		
	(i) Trade receivables	7,975.00	5,462.54
	(ii) Cash and cash equivalents	17,324.00	11,398.24
	(iii) Bank balances other than (ii) above	5.71	1,194.00
	(iv) Loans	81.08	123.94
	(v) Other financial current assets	555.63	353.71
	(c) Other current assets	2,720.09	2,243.82
	Sub-total - Current assets	40,472.25	32,091.35
	TOTAL - ASSETS	56,181.53	46,053.92
1	EQUITY AND LIABILITIES		
	Equity		
	(a) Equity Share capital	500.00	500.00
	(b) Other Equity	29,580.50	24,193.18
	Sub-total - Shareholders' funds	30,080.50	24,693.18
	LIABILITIES		
	Non-current liabilities		
	(a) Provisions	202.10	665.77
	Sub-total - Non-current liabilities	202.10	665.77
2	Current liabilities		
	(a) Financial Liabilities		
	(i) Trade payables		
	Total outstanding dues of micro enterprises and small enterprises	45.20	-
	Total outstanding dues of creditors other than micro enterprises and small enterprises	16,775.12	12,719.89
	(ii) Other financial liabilities	4,000.10	3,185.09
	(b) Other current liabilities	1,438.27	756.36
	(c) Provisions	3,457.06	3,498.12
	(d) Current tax liability	183.18	535.51
	Sub-total - Current liabilities	25,898.93	20,694.97
	TOTAL - EQUITY AND LIABILITIES	56,181.53	46,053.92



[Handwritten signature]

[Handwritten signature]